Indirect costs in chronic obstructive pulmonary disease: A review of the economic burden on employers and individuals in the United States

Abstract

Objective

To review and summarize existing literature on the indirect burden of chronic obstructive pulmonary disease (COPD) in the US.

Methods

Medline, Scopus, and OvidSP databases were searched using defined search terms to identify relevant studies. Eligible studies were published in English between January 2000 and April 2012 and calculated the indirect burden of COPD in a US population in terms of prevalence, incidence or costs of productivity loss, disability, morbidity, or mortality.

Results

Of 53 studies identified, eleven met eligibility criteria, with data years spanning 1987–2009. Estimates of workforce participation range from 56% to 69% among individuals with COPD and from 65% to 77% among individuals without COPD. Approximately 13%–18% of those with COPD are limited in the amount or type of work they can do and one-third or more experience general activity limitation. Estimates of restricted activity days range from 27–63 days per year. Estimates of mean annual sick leave and/or disability days among employed individuals with COPD range from 1.3–19.4 days. Estimates of bed confinement range from 13–32 days per year. Estimated mean annual indirect costs were $893–$2,234/person (US dollars) with COPD ($1,521–$3,348 in 2010 [US dollars]) and varied with the population studied, specific cost outcomes, and economic inputs. In studies that assessed total (direct and indirect) costs, indirect costs accounted for 27%–61% of total costs, depending on the population studied.

Conclusions

COPD is associated with substantial indirect costs. The disease places a burden on employers in terms of lost productivity and associated costs and on individuals in terms of lost income related to absenteeism, activity limitation, and disability. Consideration of indirect as well as direct costs is necessary to gain a more complete view of the societal burden of COPD.

Keywords:

• chronic obstructive pulmonary disease
• disability
• economics
• indirect costs
• productivity

Acknowledgments

The authors thank Judith S Hurley, MS, for editorial assistance.

Disclosure

Jeetvan G Patel, Saurabh P Nagar and Anand A Dalal are employees of GlaxoSmithKline (GSK); Jeetvan G Patel and Anand A Dalal own GSK stock. The authors have no other conflicts of interest to declare.